KPV 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

KPV is a tripeptide (Lysine–Proline–Valine), the C-terminal fragment of the hormone alpha-MSH, studied as an anti-inflammatory agent that appears to act inside the cell to dampen pro-inflammatory signaling such as the NF-κB pathway[1][2]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved investigational research chemical, not a medicine; the evidence is preclinical (cell and animal) with no established human efficacy — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 10 mg vial → ~3.33 mg/mL (3,333 mcg/mL), the largest practical dilution for accurate dosing.
200–500 mcg once daily, titrated upward gradually across an 8–12 week course (extendable to 16 weeks).
At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg; 200 mcg = 6 units and 500 mcg = 15 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1	200 mcg (1× daily)	6 units (0.06 mL)
Week 2	300 mcg (1× daily)	9 units (0.09 mL)
Week 3	400 mcg (1× daily)	12 units (0.12 mL)
Weeks 4–8	500 mcg (1× daily)	15 units (0.15 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration ~3.33 mg/mL (3,333 mcg/mL).
Typical daily range: 200–500 mcg once daily, raised gradually over an 8–12 week course.
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe. Each dose lands on a whole unit mark (6–15 units) for reliable measuring accuracy.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, titrating up as tolerated. The schedule begins at 200 mcg and steps up by roughly 100 mcg each week to a 400–500 mcg maintenance range[3][4]. These figures are an educational reference only, not approved human dosing.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution lands every dose on a whole unit mark (6–15 units), where U-100 syringe readings are easy and precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration.

A 10 mg vial covers several weeks at 200–500 mcg/day, so a full course needs only a few vials.
8 weeks: ~3 vials
12 weeks: ~4 vials
16 weeks: ~6 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 10 mg vial for reconstitution.
8 weeks (3 vials): ~9 mL → 1 bottle
16 weeks (6 vials): ~18 mL → 2 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Explore the anti-inflammatory activity attributed to this alpha-MSH fragment — effects reported in cell and animal models only, not established in humans[5][6].
▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
▪Dose Range: 200–500 mcg per day with gradual weekly titration.
▪Reconstitution: 3.0 mL bacteriostatic water per 10 mg vial gives ~3.33 mg/mL for accurate unit measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 200 mcg once daily to gauge tolerability.
▪Titrate: Increase by roughly 100 mcg each week as tolerated.
▪Target: Reach a 400–500 mcg daily maintenance range by weeks 4–8.
▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: KPV is an investigational research chemical and is not approved by any major regulator for human use; the evidence base is preclinical only[10].

How This Works

KPV is a tripeptide made of Lysine-Proline-Valine — the C-terminal fragment (residues 11–13) of the hormone alpha-melanocyte-stimulating hormone (α-MSH)[1][2]. It retains much of the parent hormone’s anti-inflammatory character while lacking its pigment-related (melanotropic) effects.

Its proposed mechanism is intracellular: rather than acting only at a surface receptor, KPV is thought to enter the cell and dampen pro-inflammatory signaling — including the NF-κB pathway — which in turn lowers the output of inflammatory mediators[5][6]. Much of the laboratory interest has centred on gut inflammation (models of IBD and colitis) and skin inflammation.
In preclinical work, peptide-transporter uptake (e.g. PepT1 in intestinal cells) has been described as one route by which the tripeptide reaches its intracellular targets[11]. These findings come from cell and animal studies, and the magnitude and relevance of any effect in humans remains unknown.
Important caveat: KPV is not approved by any major regulator, and there are no established human efficacy results. The evidence is entirely preclinical; reports of anti-inflammatory benefit should be read as research hypotheses, not demonstrated outcomes[13].
KPV is not an approved medicine. It is an investigational research chemical presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support general wellbeing alongside the protocol.

▪Nutrition: Favour a balanced, whole-food diet; anti-inflammatory eating patterns may complement the protocol.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid excess physical stress.
▪Sleep: Aim for 7–9 hours, since sleep influences immune and inflammatory balance.
▪Stress: Manage stress with evidence-based practices, since it influences inflammation and overall wellbeing.

Potential Benefits & Side Effects

What preclinical (cell and animal) literature describes; there is no established human evidence, and any effects are unproven.

▪Gut inflammation (preclinical): In animal models of colitis/IBD, the peptide has been reported to reduce markers of intestinal inflammation[5][6].
▪Inflammatory signaling (preclinical): Cell studies describe dampened pro-inflammatory signaling (e.g. NF-κB) and lower cytokine output[11].
▪Skin inflammation (preclinical): Topical and dermal models have explored anti-inflammatory effects on irritated skin.
▪Note on humans: None of these effects are established in humans — the evidence is preclinical and no controlled human efficacy trials support these uses[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
▪Unapproved status: KPV is not approved by any major regulator and is intended for research use only.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides. Note that a KPV 10 mg vial is not currently a listed product, so the link goes to the supplier’s main site.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for KPV 10mg.

KPV (10mg Vial) Dosage Protocol Open source
1 FASEB Journal KPV identified as the C-terminal tripeptide of alpha-MSH retaining anti-inflammatory activity. View Source ↗ Open source
2 Journal of Chromatography A (PubMed) Studies of the alpha-MSH C-terminal sequence and its anti-inflammatory tripeptide KPV. View Source ↗ Open source
3 PubMed (NCBI) Review of KPV anti-inflammatory activity in preclinical models (dose and exposure context). View Source ↗ Open source
4 Racing Medication & Testing Consortium Preclinical dosing context for small anti-inflammatory peptides such as KPV. View Source ↗ Open source
5 Journal of Investigative Dermatology (PubMed) KPV reduces intestinal inflammation in animal models of colitis/IBD. View Source ↗ Open source
6 FASEB Journal (PubMed) KPV and intestinal anti-inflammatory effects in experimental colitis models. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 FDA — Unapproved Drugs Regulatory status: KPV is an unapproved investigational research chemical, not approved for human use. View Source ↗ Open source
11 Journal of Investigative Dermatology KPV transport (e.g. via PepT1) and intracellular anti-inflammatory signaling, including NF-kB modulation. View Source ↗ Open source
12 Journal of Chromatography B (PubMed) Mechanistic studies of KPV effects on pro-inflammatory cytokine signaling in cell models. View Source ↗ Open source
13 ClinicalTrials.gov Clinical-trial registry: no completed human efficacy trials establish KPV for any indication. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides Prime Lab Peptides supplier site (KPV 10 mg is not a listed product; link goes to the main site). View Source ↗ Open source

Contents